Truseltiq (infigratinib) - BridgeBio, Pfizer, Xediton Pharma
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study) (clinicaltrials.gov) - Oct 9, 2026 - P3 | N=13 | Active, not recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Recruiting ➔ Active, not recruiting 
Enrollment closed • Genetic Disorders
http://clinicaltrials.gov/ct2/show/NCT06926491
 
Oct 9, 2026
 
Prev Next